Related Experiment Video

Updated: Aug 15, 2026

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
11:03

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model

Published on: October 30, 2019

Remittive therapy in rheumatoid arthritis: clinical uses and mechanisms of action

P E Lipsky

    Agents and Actions. Supplements
    |January 1, 1984
    PubMed

    Evidence has been reviewed supporting the conclusion that gold compounds, anti-malarials and D-penicillamine have the capacity to function as immunosuppressive drugs. Moreover, the results indicate that each has a unique site of action, specifically inhibiting the function of only one of the populations of cells likely to be involved in chronic immunologically-mediated inflammation. Gold compounds and anti-malarials appear to be active by virtue of their capacity to depress the function of mononuclear phagocytes, while D-penicillamine acts by inhibiting a number of the activities of T lymphocytes. These results imply that the means by which these drugs suppress rheumatoid inflammation are fundamentally different. Thus, while each of these compounds acts as a selective immunosuppressive agent, the target cell inhibited appears to be different. The conclusion that the remission-inducing drugs have different modes of action in RA is supported by the clinical observation that the success rate of therapy with one is comparable regardless of antecedent therapy with another (125, 126).

    More Related Videos

    Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

    Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

    Published on: May 16, 2025

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

    Published on: June 6, 2025

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Drugs Used in Lower Respiratory Disorders: Overview01:17

    Drugs Used in Lower Respiratory Disorders: Overview

    Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
    Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
    T Cell Types and Functions01:24

    T Cell Types and Functions

    When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
    Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

    Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

    The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
    Rheumatic Heart Disease III: Medical Management01:21

    Rheumatic Heart Disease III: Medical Management

    Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...